Results · Healthcare & Life Sciences

Indegene posts strong FY26 results, outlines growth roadmap

By Startup Enthusiast · 10 September 2026

What they do

FY26 revenue was ₹35,105M with a 19.4% adjusted EBITDA margin and zero debt

The company targets $2B+ revenue by expanding client tiers and capturing market share from agencies and CROs

It serves 20 of the top 20 global pharma companies and has grown active clients from 44 to 91 in five years

Indegene submitted a revised investor presentation to stock exchanges, correcting a duplicate page with no material change.
For FY26, Indegene reported ₹35,105M in revenue and an adjusted EBITDA margin of 19.4%.
The company has a zero debt balance sheet and a Net Revenue Retention above 100% every year.
Revenue per employee as of March 2026 was $74.7K, and revenue per delivery employee was $86.5K.
Indegene merged its indirect wholly owned subsidiaries Indegene Healthcare Germany GmbH and Trilogy Writing & Consulting GmbH on September 9, 2026.
The German merger involved no cash consideration or share exchange and had no material impact on the listed entity.
Indegene will host Premji Invest for an in-person one-on-one meeting on September 11, 2026 in Bengaluru.
The meeting with Premji Invest will not involve sharing any unpublished price-sensitive information.

The global pharma industry is projected to grow from $1.4Tn to $2Tn+ by 2030, with a sector CAGR of 5%-7%.
Indegene sees GenAI as a tailwind due to five structural reasons, including being a revenue partner and not a cost partner.
The company has identified high-potential accounts with $150-200M potential as priority targets.
Indegene's FY27 pipeline is 17% higher than the same point in the prior year.

Indegene is an AI-native life sciences operating partner, helping from clinical development to commercialization.
It offers end-to-end solutions including Strategy & Consulting, Discovery & Development, Launch & Commercialization, and Technology & Operational Accelerators.
The company is powered by Cortex, an intelligence layer connecting data, workflows, human expertise, and AI.
Indegene serves 20 of the top 20 and 80 of the top 100 global life sciences companies.
It has been purpose-built for life sciences for 27+ years and claims 20-30% faster decision cycles.
Revenue per employee as of March 2026 was $74.7K, and revenue per delivery employee was $86.5K.
The company has grown active client relationships from 44 in FY21 to 91 in FY26 (2.0x).
Clients with $1M+ revenue grew from 22 in FY21 to 53 in FY26 (2.4x).

Indegene targets a multi-billion dollar growth roadmap by expanding client tiers and capturing market share from agencies and CROs through AI-driven centralization.
The mid-term plan includes growing Tier 1 (strategic >$25M) clients from 3 to 9, with one crossing $100M.
It plans to grow Tier 2 ($10-25M) clients from 7 to 16 with 2x account growth.
The company aims for 50% growth in mid-size pharma in Tier 3 ($1-10M) and 1.5x growth in Tier 4 ($0.25-1M) account count.
Strategic priorities include traction in new solutions Tectonic and Medical Writing, M&A capability expansion via acquisitions of Cult, Trilogy, Biopharm, Warn, Cake Communications, and continued AI platform investment.
Indegene's current scale is approximately $400M, with a near-term target of $500M+.
The company has a stated $2B+ vision supported by consulting-led selling and a high-talent team.